Surnar Bapurao, Kolishetti Nagesh, Dhar Shanta
Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA.
Department of Immunology and Nano-Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Methods Mol Biol. 2025;2925:413-421. doi: 10.1007/978-1-0716-4534-5_28.
Atherosclerosis is attributed to one of the highest mortality rates in the United States and many other countries. Hypercholesterolemia is a significant risk factor for atherosclerosis. The balance between high-density lipoprotein (HDL) and low-density lipoprotein maintains the cholesterol levels by removing or depositing it, respectively. By synthesizing HDL-mimicking nanoparticles (NPs), the therapeutic removal of cholesterol may be plausible upon administration. In addition, HDL has been known to be an excellent transporter of various cargos. The manipulations of such characteristics could yield NPs that can target atherosclerotic plaque sites. To investigate this possibility, we developed HDL-mimicking NPs using FDA-approved polymers. This NP can participate in cholesterol efflux, possibly through a reverse cholesterol transport pathway.
动脉粥样硬化是美国和许多其他国家死亡率最高的原因之一。高胆固醇血症是动脉粥样硬化的一个重要风险因素。高密度脂蛋白（HDL）和低密度脂蛋白之间的平衡分别通过清除或沉积胆固醇来维持胆固醇水平。通过合成模仿HDL的纳米颗粒（NPs），给药后治疗性清除胆固醇可能是可行的。此外，已知HDL是各种货物的优秀转运体。对这些特性的操控可以产生能够靶向动脉粥样硬化斑块部位的纳米颗粒。为了研究这种可能性，我们使用美国食品药品监督管理局（FDA）批准的聚合物开发了模仿HDL的纳米颗粒。这种纳米颗粒可能通过逆向胆固醇转运途径参与胆固醇外流。
